LEADER 01552nam 2200397Ka 450 001 9910697521603321 005 20090204153729.0 035 $a(CKB)5470000002389739 035 $a(OCoLC)301753585 035 $a(EXLCZ)995470000002389739 100 $a20090204d1997 ua 0 101 0 $aeng 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aUsing echo intensity to correct moored ADCP data for fish-bias errors at 0?, 170?W$b[electronic resource] /$fP.E. Plimpton ... [and others] 210 1$a[Seattle, Wash.] :$c[Pacific Marine Environmental Laboratory],$d[1997] 215 $aiii, 17 pages $cdigital, PDF file 225 1 $aNOAA technical memorandum ERL PMEL ;$v111 225 1 $aContribution no. 1843 from NOAA/Pacific Marine Environmental Laboratory 300 $aTitle from title screen (viewed Feb. 3, 2009). 300 $a"August 1997." 606 $aOcean currents$zPacific Ocean$xMeasurement 606 $aOceanographic buoys$zPacific Ocean 606 $aMarine fishes$xMonitoring$zPacific Ocean$xMeasurement 615 0$aOcean currents$xMeasurement. 615 0$aOceanographic buoys 615 0$aMarine fishes$xMonitoring$xMeasurement. 701 $aPlimpton$b Patricia E$01400732 712 02$aPacific Marine Environmental Laboratory (U.S.) 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910697521603321 996 $aUsing echo intensity to correct moored ADCP data for fish-bias errors at 0?, 170?W$93532135 997 $aUNINA LEADER 04108nam 22006013 450 001 9911019785503321 005 20241207060246.0 010 $a9783527838387 010 $a3527838384 010 $a9783527838394 010 $a3527838392 010 $a9783527838370 010 $a3527838376 035 $a(MiAaPQ)EBC31812765 035 $a(Au-PeEL)EBL31812765 035 $a(CKB)36822877300041 035 $a(OCoLC)1477220064 035 $a(Perlego)4668906 035 $a(Exl-AI)31812765 035 $a(EXLCZ)9936822877300041 100 $a20241207d2025 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTrends in MRNA Vaccine Research 205 $a1st ed. 210 1$aNewark :$cJohn Wiley & Sons, Incorporated,$d2025. 210 4$d©2025. 215 $a1 online resource (428 pages) 225 1 $aTrends in Drug Discovery Series 311 08$a9783527350582 311 08$a3527350586 327 $aCover -- Title Page -- Copyright -- Contents -- Preface -- Preface from the Volume Editors -- Part I How mRNA Vaccines Work -- Chapter 1 A Historical Overview on mRNA Vaccine Development -- 1.1 Introduction -- 1.2 The Path of mRNA as an Unstable and Toxic Product to a New Class of Medicine -- 1.2.1 The Discovery and In Vitro Production of mRNA -- 1.2.2 The Inflammatory Nature of mRNA -- 1.3 How Studying Lipid Bilayer Structures in Cell Membranes Gave Rise to the Eventual Development of Lipid Nanoparticles for RNA Delivery -- 1.3.1 From Biological Cell Membranes to Liposomal Drugs -- 1.3.2 Ionizable Lipid Nanoparticles for Systemic Delivery of Nucleic Acids -- 1.4 The Journey of Developing Clinical mRNA Vaccines -- 1.5 Concluding Remarks -- References -- Chapter 2 Immune Responses to mRNA Vaccine -- 2.1 Introduction -- 2.2 Innate Sensing of RNA Molecules -- 2.3 Innate Immune Response to mRNA Vaccines -- 2.3.1 Innate Immune Response in Humans -- 2.3.2 Tissue Innate Immune Response in Mice -- 2.4 mRNA Design and Innate Immunity -- 2.4.1 Cap -- 2.4.2 Untranslated Regions -- 2.4.3 Poly(A) -- 2.4.4 Coding Sequence -- 2.5 Optimization and Production of mRNA for an Adequate Innate Immune Response$7Generated by AI. 330 8 $aThe authoritative guide to the revolutionary concept behind the successful Covid-19 vaccines In Trends in mRNA Vaccine Research, a team of distinguished researchers delivers a practical and up-to-date discussion of the biochemical and biomedical foundations of mRNA vaccines. They also explore the manufacturing conditions required for successful vaccine development and review recent progress in a variety of medical fields, including vaccines against pathogens like SARS-CoV-2, HIV, plasmodium, Mycobacterium tuberculosis, as well as anticancer vaccines. Volume highlights include: * A historical overview of mRNA vaccine development * Immune responses to modified or unmodified mRNA vaccines * A description of the different mRNA vaccine platforms * Latest data on current mRNA vaccine developments against infectious diseases and cancer Perfect for medicinal chemists, immunologists, and epidemiologists, Trends in mRNA Vaccine Research will also benefit researchers and scientists working in the pharmaceutical industry, as well as cancer researchers with an interest in vaccine development. 410 0$aTrends in Drug Discovery Series 606 $aCOVID-19 vaccines$7Generated by AI 606 $aMessenger RNA$7Generated by AI 615 0$aCOVID-19 vaccines 615 0$aMessenger RNA 700 $aSzabo$b Gabor Tamas$01842735 701 $aPardi$b Norbert$01842736 701 $aFischer$b János$0881301 701 $aKlein$b Christian$0426675 701 $aChilders$b Wayne E$01838514 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911019785503321 996 $aTrends in MRNA Vaccine Research$94422945 997 $aUNINA